Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study will be to provide further evidence of the long-term
safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in
participants with advanced Parkinson's disease (PD) and severe motor fluctuations.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Quintiles, Inc.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa